within Pharmacolibrary.Drugs.ATC.C;

model C01BC03_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.51,
    Cl             = 2.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600,            
    Vdp             = 0.0019,
    k12             = 0.41,
    k21             = 0.41
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01BC03_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Propafenone is a class 1C antiarrhythmic drug used in the treatment and prevention of supraventricular and ventricular arrhythmias. It works primarily by blocking sodium channels in the heart, reducing excitability and conduction. Propafenone is FDA-approved and remains in clinical use today.</p><h4>Pharmacokinetics</h4><p>Subjects with poor CYP2D6 metabolism (genetically poor metabolizers), oral administration, single dose.</p><h4>References</h4><ol><li><p>Ito, S, et al., &amp; Koren, G (1998). Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response. <i>Journal of clinical pharmacology</i> 38(6) 496–501. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1998.tb05786.x&quot;>10.1002/j.1552-4604.1998.tb05786.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9650538/&quot;>https://pubmed.ncbi.nlm.nih.gov/9650538</a></p></li><li><p>Zhang, H, et al., &amp; Streisand, JB (2002). Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 41(9) 661–680. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241090-00003&quot;>10.2165/00003088-200241090-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12126458/&quot;>https://pubmed.ncbi.nlm.nih.gov/12126458</a></p></li><li><p>Michaud, V, et al., &amp; Turgeon, J (2006). Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. <i>Therapeutic drug monitoring</i> 28(6) 779–783. DOI:<a href=&quot;https://doi.org/10.1097/01.ftd.0000249945.64978.33&quot;>10.1097/01.ftd.0000249945.64978.33</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17164694/&quot;>https://pubmed.ncbi.nlm.nih.gov/17164694</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01BC03_1;
